MARKET WIREYahoo Finance • 17h ago
Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey?Yahoo Finance report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
Why IAM Stock dropped -5.95% Today — RQD Quant Desk Flash
$13.43 -5.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.26
Iambic Therapeutics Inc. (IAM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $636.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IAM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Iambic Therapeutics Inc. (NASDAQ: IAM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.43 (-5.95% 1D, market cap $636.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IAM ranks #306 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IAM compare to AURA and CADL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IAM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, IAM leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IAM?
▼
For Iambic Therapeutics Inc. (IAM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #306 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.26 (-1.26%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IAM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY IAM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($17.8M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$23.81-38.4% Next Q
55
Q2 (-2Q)Grade C-$14.67+0.7% Next Q
52
Q3 (-1Q)Grade C-$14.78-9.1% Next Q
50
CurrentGrade D$13.43-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IAM Turnaround Squeeze
While IAM currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.64) and Max Pain ($14.10) forces dealer call-delta covering toward $26.25.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IAM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IAM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IAM Stock dropped -5.95% Today — RQD Quant Desk Flash
Iambic Therapeutics Inc. (IAM) dropped -5.95% to $13.43, trading at 11% of its 52-week range ($12.06 – $25). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($12.06 – $25) with RSI-14 at 38.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $13.43 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $17.8M annual free cash flow.
Live IAM Headlines & Catalysts
MARKET WIREQuartz • 20h ago
Nvidia-backed Iambic stock is up 16% in Nasdaq debut after $150 million IPOQuartz report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREFierce Biotech • 1d ago
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipelineFierce Biotech report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Iambic Therapeutics, Inc. Stock (IAM) - Quote Nasdaqwww.marketscreener.com report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Iambic Therapeutics prices 9.38M share IPO at $16.00/shareTradingView report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
Nvidia-backed Iambic stock gains on trading debut (IAM:NASDAQ)Seeking Alpha report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRENasdaq • 1d ago
Iambic Therapeutics, Inc. Rings the Nasdaq Stock Market Opening BellNasdaq report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Iambic Therapeutics (IAM) Filed An IND For IAM217Yahoo Finance report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 7d ago
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven CancersSAN DIEGO, October 26, 2026--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinic
MARKET WIREBenzinga • 7d ago
Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data for IAM1363, a
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IAM)
- ✓Walkthrough of IAM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IAM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.98%
2026-11-02O $13.43H $13.55L $12.02C $13.43VOL 402.7K
SMA50: $15.70
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IAM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IAM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IAM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IAM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IAM)
Health Care Rank #306 of 1016
⚔️ AURA vs IAM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IAM vs. AURA, CADL, FDMT, SLDB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Iambic Therapeutics Inc. (IAM) ranks #306 by composite RQD confidence (47/100, grade D) and #408 by equity capitalization ($636.6M). Within this direct 5-issuer industry benchmark cohort, IAM leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IAM
ACTIVE
Iambic Therapeutics Inc. | D | 47/100 | — | — | — | -5.95% | $636.6M | Benchmark Subject |
| AURA Aura Biosciences Inc. | E | 29/100 | — | — | -35.0% | -2.46% | $636.7M | /aura-vs-iam → |
| CADL Candel Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -3.70% | $637.4M | /cadl-vs-iam → |
| FDMT 4D Molecular Therapeutics Inc. | D | 44/100 | — | — | -28.3% | -6.89% | $657.4M | /fdmt-vs-iam → |
| SLDB Solid Biosciences Inc. | E | 26/100 | — | — | -35.0% | -2.97% | $664.8M | /sldb-vs-iam → |
2. IAM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTIambic Therapeutics Inc. (IAM) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $636.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. IAM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IAM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Iambic Therapeutics Inc. (NASDAQ: IAM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.43 (-5.95% 1D, market cap $636.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IAM ranks #306 in composite RQD confidence.
How does IAM compare to AURA and CADL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IAM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, IAM leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IAM?
For Iambic Therapeutics Inc. (IAM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #306 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IAM trading relative to its 50-day, 200-day, and 52-week technical levels?
IAM last traded at $13.43 (-5.95% on volume of 476,897 shares), positioning the stock -8.27% below its 50-day simple moving average ($14.64) and -8.33% below its 200-day simple moving average ($14.65). Across its 52-week range of $12.06 to $25.00, IAM sits at the 10.6% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.75 to $15.11).
IAM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IAM stock moving today?
Why IAM Stock dropped -5.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 47/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IAM — Iambic Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:15:11Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IAM scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
- Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. A prospective investor should note that the cash-generation pillar is not currently supplying evidence of earnings power from operations.
- Whale / 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the lowest-scoring pillar, indicating weak institutional support in the source data.
- Insider Conviction: 9 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The below-midpoint score signals limited insider-conviction signals.
- Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is factored in. The score indicates the stock is assessed as moving in line with the broad market.
- Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, though still below the midpoint of its range.
Taken together, the pillars point to a stock whose balance sheet is the most defensible element, while cash generation, institutional flow, and insider conviction are weak. For a prospective investor, the upside case rests on future clinical or commercial progress not visible in these facts, and the valuation tradeoff is that the current price of $13.43 cannot be anchored to reported earnings, since P/E and EPS are not available in source data. This brief is educational and is not personalized financial advice.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the most recent items cover the company's public listing:
- A Nasdaq debut item reported the stock rose 16% on its first trading day, following a $150 million IPO (Quartz).
- An IPO pricing item reported a 9.38M share offering at $16.00/share (TradingView).
- An IPO item reported the funding would accelerate clinical development of the oncology pipeline (Fierce Biotech).
- A Seeking Alpha item, tagged as a catalyst, reported the stock gained on trading debut.
- A Yahoo Finance item asks whether the stock is already pricey after joining the Nasdaq Composite.
Per the market data, the stock is currently $13.43, down 5.95%, and trades below its $16.00 IPO price reference. Risk watch items include the decline from the reported IPO price and the absence of financial statements. Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the company's reported revenues, operating results, and cash position, given that no financial statements are provided?
- What is the status and timing of the oncology pipeline's clinical development the IPO proceeds are intended to fund?
- Why are P/E, forward P/E, EV/EBITDA, and EPS unavailable, and how does the company's valuation compare to peers?
- What institutional, insider, and Congressional holdings exist, given that the holders and analyst data sections are empty?
- What is the lock-up and near-term share supply picture following the IPO?
IAM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Iambic Therapeutics Inc. (IAM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 17h ago
Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey? Yahoo Finance report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quartz • 20h ago
Nvidia-backed Iambic stock is up 16% in Nasdaq debut after $150 million IPO Quartz report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Fierce Biotech • 1d ago
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline Fierce Biotech report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Iambic Therapeutics, Inc. Stock (IAM) - Quote Nasdaq www.marketscreener.com report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Iambic Therapeutics prices 9.38M share IPO at $16.00/share TradingView report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
Nvidia-backed Iambic stock gains on trading debut (IAM:NASDAQ) Seeking Alpha report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Nasdaq • 1d ago
Iambic Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell Nasdaq report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Iambic Therapeutics (IAM) Filed An IND For IAM217 Yahoo Finance report covering Iambic Therapeutics Inc. (IAM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IAM Bull vs. Bear Conversation Board — What's Your Call at $13.43?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IAM 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $14.50 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IAM (D • RQD 49/100) a Buy at $13.43?
Welcome to the IAM (Iambic Therapeutics Inc.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $10.07 (-25.0%)
Spot @ $13.43 Pump the brakes on IAM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IAM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Iambic Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $17.19 (+28.0%)
Spot @ $13.43 IAM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IAM, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $13.43 (52-wk range $12.39 - $25.00), any beat on forward guidance forces shorts and underweight funds to chase.